- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07595770
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ANCRE)
13 mei 2026 bijgewerkt door: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Study on the Safety and Efficacy of Adalimumab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
Studie Overzicht
Toestand
Werving
Interventie / Behandeling
Gedetailleerde beschrijving
CROSS Study showed that the pathological complete response (pCR) rate of patients with esophageal cancer (23% of whom were esophageal squamous cell carcinoma, ESCC) after neoadjuvant radiotherapy and chemotherapy was 29%.
NEOCRTEC5010 Study showed that the pCR rate was 43.2% in locally advanced esophageal squamous cell carcinoma, which means that more than half of patients still cannot achieve ideal therapeutic effects from existing treatment options.
In addition, the recurrence rate after surgical resection compromises the long-term survival rate of patients.
Therefore, exploring new treatment strategies to improve the treatment efficacy and survival rate of esophageal cancer patients has important clinical significance.
Currently, the significance of immunotherapy combined with chemoradiotherapy in terms of pathological complete response (pCR) rates and postoperative survival quality for locally advanced esophageal squamous cell carcinoma remains unclear.
Therefore, this study aims to systematically evaluate the safety and efficacy of adebrelimab in combination with paclitaxel, carboplatin, and short-course radiotherapy as neoadjuvant therapy for ESCC.
By integrating immunotherapy with existing standard treatment regimens, this study seeks to significantly improve pCR rates, optimize surgical resection outcomes, ultimately prolong disease-free survival (DFS), and enhance overall survival (OS).
The implementation of this study is expected to provide innovative approaches and methods for the clinical treatment of ESCC, holding important clinical application value and significance.
Studietype
Ingrijpend
Inschrijving (Geschat)
37
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Baisheng Chen, M.D, PhD
- Telefoonnummer: +86-13560471611
- E-mail: Pason06213367@163.com
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Werving
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Contact:
- Baisheng Chen Chen
- Telefoonnummer: +86-13560471611
- E-mail: Pason06213367@163.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- - 1. Provided informed consent and sign the informed consent form;
- 2. Male or female, Aged 18-75 years (counted on the date of signing informed consent);
- 3. Pathological confirmed ESCC;
- 4. Patients assessed by thoracic oncologists as resectable without distant metastasis
- 5. Patients evaluate with clinical staging of T1-4aN1-3M0 or T3-4aN0M0(AJCC 9.0) based on imaging and pathological examination results;
- 6. Have at least one assessable lesion according to the RECIST V1.1
- 7. ECOG-PS score: 0-1;
- 8. Patients with normal function of organs such as heart, brain, lungs, and kidneys who can tolerate surgery;
- 9. With a life expectancy of ≥ 6 weeks;
- 10. Adequate major organ function without severe hematologic, cardiac, pulmonary, hepatic, renal, or bone marrow dysfunction, and no immunodeficiency disease;
Exclusion Criteria:
- 1. Patients who have received or are currently receiving chemotherapy, radiotherapy, immunotherapy, or targeted therapy
- 2. Patients with distant metastasis or inability to undergo resection after evaluation by thoracic surgeons
- 3. Simultaneously developing tumors in other parts of the body
- 4. Severe impairment of heart, liver, and kidney function (heart function grade 3-4, ALT and/or AST exceeding the upper limit of normal by more than 1.5 times, Cr (serum creatinine) exceeding the upper limit of normal by more than 1.5 times)
- 5. Patients with a history of autoimmune diseases who were receiving immunosuppressive therapy prior to enrollment, with immunosuppressive doses>10 mg/day or oral prednisone for more than 2 weeks
- 6. Severe allergy to immune preparations
- 7. Abnormal coagulation function: (PT>16s, APTT>53s, TT>21s, Fib<1.5 g/L), bleeding tendency or during thrombolytic or anticoagulant therapy
- 8. Pregnancy or lactation period
- 9. Other situations as judged by investigators not suitable for inclusion.;
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Adebrelimab and nab-paclitaxel plus carboplatin followed by radiotherapy
Patients would receive Adebrelimab (IV 1200mg d1) and nab-paclitaxel (IV 220 mg/m²d1) plus carboplatin (AUC = 5, d1) for two 21-day cycles, followed by one week off for radiotherapy (2.5 ⨉12 Gy).
After radiotherapy, another cycle of Adebrelimab (IV 1200mg d1) would be given.
4 to 6 weeks after completing the neoadjuvant therapy, patients would undergo esophagectomy.
|
Patients would receive Adebrelimab (IV 1200mg d1) and nab-paclitaxel (IV 220 mg/m²d1) plus carboplatin (AUC = 5, d1) for two 21-day cycles, followed by one week off for radiotherapy (2.5 ⨉12 Gy).
After radiotherapy, another cycle of Adebrelimab (IV 1200mg d1) would be given.
4 to 6 weeks after completing the neoadjuvant therapy, patients would undergo esophagectomy.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pathological complete response (pCR)
Tijdsspanne: From patient enrollment to the end of surgery
|
The proportion of subjects with no residual viable tumor cells(ypT0N0) in the primary tumor and lymph nodes; that is, the proportion of patients who have achieved complete remission among PPS(Per-Protocol Set).
|
From patient enrollment to the end of surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
R0 resection rate
Tijdsspanne: From patient enrollment to the end of surgery
|
The proportion of patients with tumor margins showing no residual cancer cells under the microscope after surgical resection.
That is, the proportion of patients in PPS achieving R0 resection.
|
From patient enrollment to the end of surgery
|
|
Disease free survival (DFS)
Tijdsspanne: up to 24 months post-surgery
|
Disease free survival (DFS) refers to the time from the start of treatment until disease recurrence or death from any cause, whichever occurs first.
|
up to 24 months post-surgery
|
|
Overall survival (OS)
Tijdsspanne: up to 24 months after surgery
|
OS is the time interval from the start of treatment to death due to any reason or loss of follow-up
|
up to 24 months after surgery
|
|
Major pathological remission (MPR)
Tijdsspanne: From patient enrollment to the end of surgery
|
Major pathological remission (MPR) refers to the percentage of residual tumor cells in the tumor bed after neoadjuvant therapy being ≤ 10%, regardless of whether there are residual tumor cells in the lymph nodes.
|
From patient enrollment to the end of surgery
|
|
Progression free survival (PFS)
Tijdsspanne: Up to 24 months post-surgery
|
PFS is defined as the time from the start of treatment to the date of first documentation of disease progression, or date of death, whichever occurred first.
|
Up to 24 months post-surgery
|
|
Event free survival (EFS)
Tijdsspanne: From patient enrollment to the end of surgery
|
EFS refers to the time from the start of treatment to the occurrence of any event, including disease progression, cessation of treatment for any reason, or death.
|
From patient enrollment to the end of surgery
|
|
Adverse Events
Tijdsspanne: from the first drug administration to within 30 days for the last Adebrelimab dose
|
Number of adverse events.
The evaluation criteria for adverse reactions are based on the American Cancer Institute Common Adverse Event Terminology 4.0 (CTCAE 5.0) and the Acute Radiation Injury Grading Standards of the American Oncology Radiotherapy Collaboration Group (RTOG).
|
from the first drug administration to within 30 days for the last Adebrelimab dose
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
22 mei 2026
Primaire voltooiing (Geschat)
1 januari 2028
Studie voltooiing (Geschat)
1 oktober 2029
Studieregistratiedata
Eerst ingediend
13 mei 2026
Eerst ingediend dat voldeed aan de QC-criteria
13 mei 2026
Eerst geplaatst (Werkelijk)
19 mei 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
19 mei 2026
Laatste update ingediend die voldeed aan QC-criteria
13 mei 2026
Laatst geverifieerd
1 mei 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Hoofd- en nekneoplasmata
- Neoplasmata, glandulair en epitheel
- Slokdarmaandoeningen
- Carcinoom
- Neoplasmata, plaveiselcel
- Carcinoom, plaveiselcel
- Slokdarmneoplasmata
- Slokdarm plaveiselcelcarcinoom
- Organische chemicaliën
- Therapeutica
- Coördinatiecomplexen
- Carboplatine
- Radiotherapie
- 130-nm albumine-gebonden Paclitaxel
Andere studie-ID-nummers
- SYSKY-2025-799-02
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .